alexa HAGE-derived Vaccines For The Treatment Of Patients With TNBC Patients That Are Predicted To Have High Risk Of Relapsed And Poor Survival Rate, As Assessed By A Newly Identified Immune-gene Signature | 71417
ISSN: 2155-6121

Journal of Allergy & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

11th International Conference on ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY

Stephanie E McArdle, Divya Nagarajan, Gemma Foulds, Lindy Durrant, Dennis Christensen, Stephen Y T Chan, Sergio Rutella and A Graham Pockley
The John van Geest Cancer Research Centre, Nottingham Trent University, Clifton campus, Nottingham, NG11 8NS
Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK.
Statens Serum Institut, 5 Artillerivej, DK-2300 Copenhagen S, Denmark.
Clinical Oncology Department, Nottingham University Hospitals, Nottingham NG5 1PB, UK
Posters & Accepted Abstracts: J Allergy Ther
DOI: 10.4172/2155-6121-C1-006
Abstract
Triple Negative Breast Cancer (TNBC) consists of very heterogeneous subgroups of breast cancers with significant clinical challenge, the prognosis and treatment of which remains poor and limited due to the lack of targeting structures for existing therapies. We hypothesised that disease recurrence and therapeutic resistance in those patients could be influenced/predicted by tumour-related immune-regulatory events that are reflected by changes in the immune phenotypes in the periphery. It is conceivable that the analysis of immune gene transcripts in the blood will inform clinical decisions and help predict which patients are likely to respond/benefit from chemo- and/or immune-therapy. Although, breast cancer has not traditionally been viewed as being particularly susceptible to immunotherapeutic approaches, recent evidence has demonstrated a role for immune surveillance in determining patient outcome. Moreover, recent data suggest that some patients with TNBC may benefit from immune-stimulating therapies that may act synergistically when combined with chemotherapeutic drugs and tumour vaccines targeting cancer specific antigens (CSAs) expressed in TNBC. We have found that the cancer testis antigen HAGE (DDX43, CT13) is expressed in 43% of patients with TNBC. In this study, we have assessed the potential value of a newly identified HAGE-derived vaccine, as administered using two different delivery systems, for the treatment of TNBC patients using pre-clinical models. We have also used the nanoString nCounterâ„¢ FLEX amplification-free gene profiling platform to determine whether the immune-related-gene profiles in the PBMC of TNBC patients could predict patients with high risk of recurrence and poor survival rate. We therefore propose that TNBC patients with such a gene profile may benefit from a HAGE-derived vaccine.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

bioche[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7